KDEV Stock Overview
A venture capital firm specializing in investments in growth capital, seed stage, and early stage companies. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Karolinska Development AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 1.00 |
| 52 Week High | SEK 1.70 |
| 52 Week Low | SEK 0.94 |
| Beta | 0.25 |
| 1 Month Change | -2.52% |
| 3 Month Change | 1.11% |
| 1 Year Change | -36.78% |
| 3 Year Change | -70.64% |
| 5 Year Change | -71.40% |
| Change since IPO | -97.49% |
Recent News & Updates
Recent updates
We Think That There Are Some Issues For Karolinska Development (STO:KDEV) Beyond Its Promising Earnings
May 04
Is Karolinska Development (STO:KDEV) Using Too Much Debt?
Aug 19Karolinska Development AB (publ)'s (STO:KDEV) CEO Might Not Expect Shareholders To Be So Generous This Year
Apr 27We're Not So Sure You Should Rely on Karolinska Development's (STO:KDEV) Statutory Earnings
Feb 08
Shareholder Returns
| KDEV | SE Pharmaceuticals | SE Market | |
|---|---|---|---|
| 7D | -3.6% | 2.1% | -1.2% |
| 1Y | -36.8% | -0.7% | 2.0% |
Return vs Industry: KDEV underperformed the Swedish Pharmaceuticals industry which returned -0.7% over the past year.
Return vs Market: KDEV underperformed the Swedish Market which returned 2% over the past year.
Price Volatility
| KDEV volatility | |
|---|---|
| KDEV Average Weekly Movement | 5.0% |
| Pharmaceuticals Industry Average Movement | 8.6% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in SE Market | 12.9% |
| 10% least volatile stocks in SE Market | 3.5% |
Stable Share Price: KDEV has not had significant price volatility in the past 3 months compared to the Swedish market.
Volatility Over Time: KDEV's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 8 | Viktor Drvota | www.karolinskadevelopment.com |
Karolinska Development AB (publ) is a venture capital firm specializing in investments in growth capital, seed stage, and early stage companies. It seeks to invest in pharmaceutical research and development, medical research, medical innovations, healthcare technology, gene research and development, drug delivery technologies, biotechnology, and life science tools and service sectors. The firm seeks to invest in the Nordic region with a focus on Sweden, Iceland, Norway, Finland, and Denmark.
Karolinska Development AB (publ) Fundamentals Summary
| KDEV fundamental statistics | |
|---|---|
| Market cap | SEK 270.91m |
| Earnings (TTM) | -SEK 8.10m |
| Revenue (TTM) | SEK 1.84m |
147.4x
P/S Ratio-33.4x
P/E RatioIs KDEV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| KDEV income statement (TTM) | |
|---|---|
| Revenue | SEK 1.84m |
| Cost of Revenue | SEK 0 |
| Gross Profit | SEK 1.84m |
| Other Expenses | SEK 9.94m |
| Earnings | -SEK 8.10m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
Apr 30, 2025
| Earnings per share (EPS) | -0.03 |
| Gross Margin | 100.00% |
| Net Profit Margin | -440.75% |
| Debt/Equity Ratio | 0% |
How did KDEV perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/23 18:22 |
| End of Day Share Price | 2025/03/21 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Karolinska Development AB (publ) is covered by 6 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Johan Löchen | ABG Sundal Collier Sponsored |
| Espen Jørgensen | DNB Markets |
| Sachin Soni | Kempen & Co. NV |